Shiny K. Kajal/LinkedIn
Mar 3, 2026, 17:04
Shiny K Kajal: Therapeutic Apheresis Is Redefining the Clinical Scope of Transfusion Medicine
Shiny K Kajal, Senior Resident at Adesh University, shared a post on LinkedIn:
“Post 29 – When most people think of transfusion medicine, they think of blood bags and compatibility testing.
But modern Immunohematology and Blood Transfusion goes far beyond that.
Therapeutic Apheresis allows selective removal of disease-causing components directly from circulation – offering rapid clinical benefit in several critical conditions.
Key Apheresis Modalities
- Therapeutic Plasma Exchange (TPE) – Removal of pathogenic plasma components
- Red Cell Exchange – Replacement of abnormal erythrocytes
- Leukapheresis – Rapid cytoreduction in leukocytosis
- Plateletpheresis – Control of extreme thrombocytosis
- LDL Apheresis – Removal of atherogenic lipoproteins
From autoimmune diseases to hematologic emergencies, therapeutic apheresis is redefining the clinical scope of transfusion medicine.
Not just transfusing blood — but therapeutically transforming it.”
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 17:28Jim Hoffman: New Potential Predictive Biomarker for Lupus Nephritis
-
Sep 13, 2026, 17:08W. Alberto Sifuentes Giraldo: Urticarial Vasculitis Clinical Features, Systemic Involvement, and Treatment
-
Sep 13, 2026, 16:58Let’s Debunk Some Myths about Blood in SCD – ASCO
-
Sep 13, 2026, 16:56William Wallace: A Magnesium Ion Decides Whether Your Brain Learns or Not
-
Sep 13, 2026, 16:54Meet NBDF’s 2026 Excellence Fellowship Recipients – National Bleeding Disorders Foundation
-
Sep 13, 2026, 16:52Kaloyan Takov: Native Lp(a) Carries a Distinct Triglyceride Signature Linked to Cardiovascular Disease
-
Sep 13, 2026, 16:51Axay Tomar: How Simulation-Based Education Shapes Safer Transfusion Practices
-
Sep 13, 2026, 16:51Edina Cenko: AZURE-HeFH Highlights the LDL-C Treatment Gap in HeFH
-
Sep 13, 2026, 16:49William Aird: Why Is LDH Elevated In Splenic Infarction?